Nautilus Biotechnology (NASDAQ:NAUT) is a biotechnology company focused on advancing proteomics research through a proprietary single-cell proteomics platform. Headquartered in Seattle, Washington, the company has developed an integrated system that combines robotics, microfluidics and advanced optics to deliver high-sensitivity, high-throughput protein analysis. Nautilus’s platform is designed to quantify thousands of proteins and post-translational modifications from individual cells, enabling researchers to explore cellular complexity with unprecedented depth and precision.
The core offering of Nautilus Biotechnology is its end-to-end proteomics solution, which includes automated sample preparation, in-line quality control and a data processing pipeline powered by proprietary software algorithms. This platform supports a range of applications, from basic biological research to target discovery and biomarker validation in drug development. Customers gain access to customizable assay development services and collaborative research partnerships, allowing them to tailor experiments to specific disease areas or therapeutic modalities.
Since its founding in 2019, Nautilus Biotechnology has forged relationships with academic institutions, pharmaceutical companies and research laboratories across North America, Europe and Asia. The company’s approach addresses long-standing challenges in proteome coverage, reproducibility and scalability, making it a valuable partner for organizations seeking to accelerate translational research. Nautilus continues to expand its global reach through strategic collaborations and service offerings that bridge the gap between proteomic data generation and actionable biological insights.
Led by co-founder and Chief Executive Officer Steve McClatchy, Nautilus’s leadership team comprises industry veterans from leading life science instrumentation and biotechnology firms. The company’s management and scientific advisory board bring extensive experience in microfluidics, mass spectrometry and bioinformatics, guiding Nautilus’s efforts to commercialize its technology and drive innovation in the rapidly evolving field of proteomics.
